Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth

Himanshu Arora, Kush Panara, Manish Kuchakulla, Shathiyah Kulandavelu, Kerry L Burnstein, Andrew V Schally, Joshua Hare, Ranjith Ramasamy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Immune targeted therapy of nitric oxide (NO) synthases are being considered as a potential frontline therapeutic to treat patients diagnosed with locally advanced and metastatic prostate cancer. However, the role of NO in castration-resistant prostate cancer (CRPC) is controversial because NO can increase in nitrosative stress while simultaneously possessing antiinflammatory properties. Accordingly, we tested the hypothesis that increased NO will lead to tumor suppression of CRPC through tumor microenvironment. Snitrosoglutathione (GSNO), an NO donor, decreased the tumor burden in murine model of CRPC by targeting tumors in a cell nonautonomous manner. GSNO inhibited both the abundance of antiinflammatory (M2) macrophages and expression of pERK, indicating that tumor-associated macrophages activity is influenced by NO. Additionally, GSNO decreased IL-34, indicating suppression of tumor-associated macrophage differentiation. Cytokine profiling of CRPC tumor grafts exposed to GSNO revealed a significant decrease in expression of G-CSF and M-CSF compared with grafts not exposed to GSNO. We verified the durability of NO on CRPC tumor suppression by using secondary xenograft murine models. This study validates the significance of NO on inhibition of CRPC tumors through tumor microenvironment (TME). These findings may facilitate the development of previously unidentified NO-based therapy for CRPC.

Original languageEnglish (US)
Pages (from-to)11298-11303
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number44
DOIs
StatePublished - Oct 30 2018

Fingerprint

Tumor Microenvironment
Castration
Prostatic Neoplasms
Nitric Oxide
Growth
Neoplasms
Macrophage Colony-Stimulating Factor
Macrophages
Anti-Inflammatory Agents
Transplants
Nitric Oxide Donors
Granulocyte Colony-Stimulating Factor
Tumor Burden
Heterografts
Nitric Oxide Synthase
Therapeutics
Cytokines

Keywords

  • CRPC
  • Immunotherapy
  • Nitric oxide
  • Tumor microenvironment
  • Tumor-associated macrophages

ASJC Scopus subject areas

  • General

Cite this

Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth. / Arora, Himanshu; Panara, Kush; Kuchakulla, Manish; Kulandavelu, Shathiyah; Burnstein, Kerry L; Schally, Andrew V; Hare, Joshua; Ramasamy, Ranjith.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, No. 44, 30.10.2018, p. 11298-11303.

Research output: Contribution to journalArticle

@article{c64ec3a06c4642d8a7d3454e487958cf,
title = "Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth",
abstract = "Immune targeted therapy of nitric oxide (NO) synthases are being considered as a potential frontline therapeutic to treat patients diagnosed with locally advanced and metastatic prostate cancer. However, the role of NO in castration-resistant prostate cancer (CRPC) is controversial because NO can increase in nitrosative stress while simultaneously possessing antiinflammatory properties. Accordingly, we tested the hypothesis that increased NO will lead to tumor suppression of CRPC through tumor microenvironment. Snitrosoglutathione (GSNO), an NO donor, decreased the tumor burden in murine model of CRPC by targeting tumors in a cell nonautonomous manner. GSNO inhibited both the abundance of antiinflammatory (M2) macrophages and expression of pERK, indicating that tumor-associated macrophages activity is influenced by NO. Additionally, GSNO decreased IL-34, indicating suppression of tumor-associated macrophage differentiation. Cytokine profiling of CRPC tumor grafts exposed to GSNO revealed a significant decrease in expression of G-CSF and M-CSF compared with grafts not exposed to GSNO. We verified the durability of NO on CRPC tumor suppression by using secondary xenograft murine models. This study validates the significance of NO on inhibition of CRPC tumors through tumor microenvironment (TME). These findings may facilitate the development of previously unidentified NO-based therapy for CRPC.",
keywords = "CRPC, Immunotherapy, Nitric oxide, Tumor microenvironment, Tumor-associated macrophages",
author = "Himanshu Arora and Kush Panara and Manish Kuchakulla and Shathiyah Kulandavelu and Burnstein, {Kerry L} and Schally, {Andrew V} and Joshua Hare and Ranjith Ramasamy",
year = "2018",
month = "10",
day = "30",
doi = "10.1073/pnas.1812704115",
language = "English (US)",
volume = "115",
pages = "11298--11303",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "44",

}

TY - JOUR

T1 - Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth

AU - Arora, Himanshu

AU - Panara, Kush

AU - Kuchakulla, Manish

AU - Kulandavelu, Shathiyah

AU - Burnstein, Kerry L

AU - Schally, Andrew V

AU - Hare, Joshua

AU - Ramasamy, Ranjith

PY - 2018/10/30

Y1 - 2018/10/30

N2 - Immune targeted therapy of nitric oxide (NO) synthases are being considered as a potential frontline therapeutic to treat patients diagnosed with locally advanced and metastatic prostate cancer. However, the role of NO in castration-resistant prostate cancer (CRPC) is controversial because NO can increase in nitrosative stress while simultaneously possessing antiinflammatory properties. Accordingly, we tested the hypothesis that increased NO will lead to tumor suppression of CRPC through tumor microenvironment. Snitrosoglutathione (GSNO), an NO donor, decreased the tumor burden in murine model of CRPC by targeting tumors in a cell nonautonomous manner. GSNO inhibited both the abundance of antiinflammatory (M2) macrophages and expression of pERK, indicating that tumor-associated macrophages activity is influenced by NO. Additionally, GSNO decreased IL-34, indicating suppression of tumor-associated macrophage differentiation. Cytokine profiling of CRPC tumor grafts exposed to GSNO revealed a significant decrease in expression of G-CSF and M-CSF compared with grafts not exposed to GSNO. We verified the durability of NO on CRPC tumor suppression by using secondary xenograft murine models. This study validates the significance of NO on inhibition of CRPC tumors through tumor microenvironment (TME). These findings may facilitate the development of previously unidentified NO-based therapy for CRPC.

AB - Immune targeted therapy of nitric oxide (NO) synthases are being considered as a potential frontline therapeutic to treat patients diagnosed with locally advanced and metastatic prostate cancer. However, the role of NO in castration-resistant prostate cancer (CRPC) is controversial because NO can increase in nitrosative stress while simultaneously possessing antiinflammatory properties. Accordingly, we tested the hypothesis that increased NO will lead to tumor suppression of CRPC through tumor microenvironment. Snitrosoglutathione (GSNO), an NO donor, decreased the tumor burden in murine model of CRPC by targeting tumors in a cell nonautonomous manner. GSNO inhibited both the abundance of antiinflammatory (M2) macrophages and expression of pERK, indicating that tumor-associated macrophages activity is influenced by NO. Additionally, GSNO decreased IL-34, indicating suppression of tumor-associated macrophage differentiation. Cytokine profiling of CRPC tumor grafts exposed to GSNO revealed a significant decrease in expression of G-CSF and M-CSF compared with grafts not exposed to GSNO. We verified the durability of NO on CRPC tumor suppression by using secondary xenograft murine models. This study validates the significance of NO on inhibition of CRPC tumors through tumor microenvironment (TME). These findings may facilitate the development of previously unidentified NO-based therapy for CRPC.

KW - CRPC

KW - Immunotherapy

KW - Nitric oxide

KW - Tumor microenvironment

KW - Tumor-associated macrophages

UR - http://www.scopus.com/inward/record.url?scp=85055671587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055671587&partnerID=8YFLogxK

U2 - 10.1073/pnas.1812704115

DO - 10.1073/pnas.1812704115

M3 - Article

C2 - 30322928

AN - SCOPUS:85055671587

VL - 115

SP - 11298

EP - 11303

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 44

ER -